57676-51-4

Basic information

• Product Name: (4-CHLORO-PHENYL)-ACETIC ACID HYDRAZIDE
• Synonyms: ASISCHEM D13397;ART-CHEM-BB B014952;CHEMBRDG-BB 3014952;2-(4-CHLOROPHENYL)ACETOHYDRAZIDE;(4-CHLORO-PHENYL)-ACETIC ACID HYDRAZIDE;AKOS B014952;AKOS BBB/175;2-(4-chlorophenyl)acetohydrazide(SALTDATA: FREE)
• CAS NO: 57676-51-4
• Molecular Formula: C₈H₉ClN₂O
• Molecular Weight: 184.62
• Mol File: 57676-51-4.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 394.9 °C at 760 mmHg
• Flash Point: 192.6 °C
• Appearance: /
• Density: 1.283 g/cm³
• Vapor Pressure: 1.91E-06mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (4-CHLORO-PHENYL)-ACETIC ACID HYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-CHLORO-PHENYL)-ACETIC ACID HYDRAZIDE(57676-51-4)
• EPA Substance Registry System: (4-CHLORO-PHENYL)-ACETIC ACID HYDRAZIDE(57676-51-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 57676-51-4(Hazardous Substances Data)

Usage

General Description

(4-CHLORO-PHENYL)-ACETIC ACID HYDRAZIDE is a chemical compound commonly used in the pharmaceutical industry. It is an intermediary product in the synthesis of various pharmaceuticals and agrochemicals. (4-CHLORO-PHENYL)-ACETIC ACID HYDRAZIDE has shown potential as an anti-tumor compound, and research is ongoing to explore its application in the treatment of cancer. Additionally, it is used as a key building block in the synthesis of various organic compounds and is valuable in the production of pharmaceuticals and other fine chemicals. This chemical has potential applications in medicine, agriculture, and other industries due to its versatile properties and potential therapeutic benefits.

InChI:InChI=1/C8H9ClN2O/c9-7-3-1-6(2-4-7)5-8(12)11-10/h1-4H,5,10H2,(H,11,12)

Upstream product

• 14062-24-9 4-chloro-benzeneacetic acid, ethyl ester 
• 140-53-4 p-chlorobenzyl cyanide 
• 25026-34-0 4-chlorophenacetyl chloride 
• 1878-66-6 4-chlorophenylacetic Acid 
• 226957-05-7 tert-butyl 2-(2-(4-chlorophenyl)acetyl)hydrazinecarboxylate 

Downstream Products

• 115601-14-4 4-Chlorphenylacetylazid 
• 34547-04-1 5-(4-chloro-benzyl)-3H-[1,3,4]oxadiazol-2-one 
• 57676-24-1 2,2'-bis-(4-chloro-benzyl)-4,5,4',5'-tetrahydro-4,4'-(2-oxa-propane-1,3-diyl)-bis-[1,3,4]oxadiazole 
• 890595-11-6 C₁₆H₁₆ClN₃O₃ 
• 129027-72-1 3-Amino-3-{[2-(4-chloro-phenyl)-acetyl]-hydrazono}-propionic acid ethyl ester 
• 896543-45-6 C₁₇H₁₈ClN₃O₃ 
• 187143-92-6 (4-Chloro-phenyl)-acetic acid [1-amino-2-cyano-eth-(E)-ylidene]-hydrazide 
• 176860-51-8 3-(1H-Imidazol-4-yl)-propionic acid N'-[2-(4-chloro-phenyl)-acetyl]-hydrazide 
• 52449-43-1 (4-chloro-phenyl)-acetic acid methyl ester 
• 126381-26-8 3-(4-Chlorphenylmethyl)-4-(p-methoxyphenyl)-1,2,4-triazolin-5-on 
• 126381-27-9 3-(4-Chlorphenylmethyl)-4-(p-ethoxyphenyl)-1,2,4-triazolin-5-on 
• 126381-28-0 3-(4-Chlorphenylmethyl)-4-(p-n-butoxyphenyl)-1,2,4-triazolin-5-on 
• 129027-77-6 5-Amino-2-[2-(4-chloro-phenyl)-acetyl]-2,4-dihydro-pyrazol-3-one 
• 129027-83-4 2-[2-(4-Chloro-phenyl)-acetyl]-4-hydroxy-4-methyl-3a,4,5,6-tetrahydro-2H-pyrrolo[2,3-c]pyrazol-3-one 

Relevant articles and documents

Carbazole-based semicarbazones and hydrazones as multifunctional anti-Alzheimer agents

With the aim to combat a multi-faceted neurodegenerative Alzheimer’s disease (AD), a series of carbazole-based semicarbazide and hydrazide derivatives were designed, synthesized and assessed for their cholinesterase (ChE) inhibitory, antioxidant and biometal chelating activity. Among them, (E)-2-((9-ethyl-9H-carbazol-3-yl)methylene)-N-(pyridin-2-yl)hydrazinecarbothioamide (62) and (E)-2-((9-ethyl-9H-carbazol-3-yl)methylene)-N-(5-chloropyridin-2-yl)hydrazinecarbothioamide (63) emerged as the premier candidates with good ChE inhibitory activities (IC50 values of 1.37 μM and 1.18 μM for hAChE, IC50 values of 2.69 μM and 3.31 μM for EqBuChE, respectively). All the test compounds displayed excellent antioxidant activity (reduction percentage of DPPH values for compounds (62) and (63) were 85.67% and 84.49%, respectively at 100 μM concentration). Compounds (62) and (63) conferred specific copper ion chelating property in metal chelation study. Molecular docking studies of compounds (62) and (63) indicate strong interactions within the active sites of both the ChE enzymes. Besides that, these compounds also exhibited significant in silico drug-like pharmacokinetic properties. Thus, taken together, they can serve as a starting point in the designing of multifunctional ligands in pursuit of potential anti-AD agents that might further prevent the progression of ADs. Communicated by Ramaswamy H. Sarma.

Synthesis and structure-activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: High affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment

Somatostatin receptor-4 (SST4) is highly expressed in brain regions affiliated with learning and memory. SST4 agonist treatment may act to mitigate Alzheimer's disease (AD) pathology. An integrated approach to SST4 agonist lead optimization is presented herein. High affinity and selective agonists with biological efficacy were identified through iterative cycles of a structure-based design strategy encompassing computational methods, chemistry, and preclinical pharmacology. 1,2,4-Triazole derivatives of our previously reported hit (4) showed enhanced SST4 binding affinity, activity, and selectivity. Thirty-five compounds showed low nanomolar range SST4 binding affinity, 12 having a Ki 500-fold affinity for SST4 as compared to SST2A. SST4 activities were consistent with the respective SST4 binding affinities (EC50 600-fold selectivity over SST2A) display a favorable physiochemical profile, and was advanced to learning and memory behavior evaluations in the senescence accelerated mouse-prone 8 model of AD-related cognitive decline. Chronic administration enhanced learning with i.p. dosing (1 mg kg-1) compared to vehicle. Chronic administration enhanced memory with both i.p. (0.01, 0.1, 1 mg kg-1) and oral (0.01, 10 mg kg-1) dosing compared to vehicle. This study identified a novel series of SST4 agonists with high affinity, selectivity, and biological activity that may be useful in the treatment of AD. This journal is

3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF

The present disclosure describes novel compounds that are somatostatin receptor type 4 agonists.